BIOSCAN - About

				ABOUT BIOSCAN

At a Glance
Key Markets
Customers
Executive Team
Company History
Employees
Offices
News Releases
Bioscan in the News
Events
Investors

At a Glance

Bioscan is one of the industry’s leading developers of advanced instrumentation for the synthesis and detection of radiolabeled compounds used in life science research, pharmaceutical development, and nuclear medicine. Its team of scientists and engineers designs, produces, and services equipment which produces radiopharmaceuticals, performs quality control procedures, and measures the results of key in vivo and in vitro experiments using a wide range of radioisotopes.

Key Markets

Positron Emission tomography (PET) is one of the fastest-growing areas of research and clinical practice. Bioscan provides key equipment for the commercial production of FDG, the main radiopharmaceutical used in the clinical practice of PET.

Bioscan also provides key radiochromatography detection equipment used in the production of radiopharmaceuticals and in the development of key radiolabeled compounds for life science and pharmaceutical research.

The current work in nuclear medicine and PET is stimulating new life science research using in vivo molecular imaging. The use of radiolabeled compounds allows the study of biochemical processes in living animals, where the complex nature of diseases and cures can be studied in detail. Bioscan’s current market position provides a strong foundation for its entrance into this rapidly emerging area.

Customers

More than 800 universities, government agencies and pharmaceutical companies use Bioscan’s products in biomedical research and the commercial clinical production of radiopharmaceuticals.

Executive Team

Seth D. Shulman, Ph.D., Chairman and Chief Technology Officer
Ted Kleinman, President and Chief Executive Officer
Staf Van Cauter, Executive Consultant for Sales, Marketing and Business Development
Victor Tchiprout, Director of Sales and Marketing
Dennis Rosatelli, Acting Chief Financial Officer

Company History

Bioscan was founded in 1980 as a supplier of innovative products for radioisotope detection and analysis in life science, pharmaceutical, and nuclear medicine research applications. The companys move into PET chemistry began in the late 1990s as an outgrowth of its involvement in nuclear medicine. Today, the company derives the majority of its revenues from sales of PET and nuclear medicine related equipment.

Employees

Offices

Headquarters –Washington, D.C.
Outside Sales Office –Chicago
European Sales and Distribution –France

PRODUCTS & SERVICES

Bioscan offers a wide variety of instruments for nuclear medicine chemistry, PET radiopharmaceutical production and life science research. These products include automated PET chemistry synthesizers, radiochromatography analytical instruments, and liquid scintillation and luminescence detectors. The company also offers technical consulting and support services to enhance the value of its products in both research and commercial radiopharmaceutical production.